Equillium, Inc.

Piper Sandler initiated coverage with an overweight rating and a $20 price target, viewing Equillium as undervalued relative to competitors in the ulcerative colitis space. Oppenheimer also reaffirmed its Outperform rating, citing positive clinical data from a competitor that supports EQ504's outlook in a market projected to exceed $12 billion globally by 2030.

Weiss Ratings reaffirmed a sell rating, and Zacks Research downgraded Equillium to a strong sell, signaling deep skepticism about the company's near-term prospects. With EQ504's Phase 1 trial only on track to start in mid-2026, the path to commercialization remains long and uncertain, leaving significant execution risk ahead.

Equillium maintains a strong balance sheet with a current ratio of 18.62 and more cash than debt. The $26 million upfront payment from the Ono agreement, along with a potential merger adding $33 million to the balance sheet, provides a meaningful financial runway to fund ongoing clinical development without immediate capital concerns.

Equillium reported a net income of -$22.40 million annually, with EPS losses expected to worsen from -$0.24 to -$0.25 per share in the next year. The company missed Q1 2026 consensus EPS estimates, and analysts explicitly do not expect profitability this year, raising concerns about long-term financial viability.

Ten brokerages covering Equillium have assigned an average Moderate Buy recommendation, with a consensus 1-year price target of approximately $7.57. Leerink upgraded the stock to Outperform, and Piper Sandler set a $20 price target, reflecting strong conviction that the stock is significantly undervalued at current trading levels.

Despite the broad buy consensus, price targets vary wildly from $4 to $20, revealing deep disagreement about intrinsic value. The stock traded at just $2.62 with a 52-week low of $0.36, and technical analysis indicates a falling short-term trend with a sell signal, suggesting the optimistic price targets may be disconnected from market reality.